Date of this Version

2024

Document Type

DNP Project

Rights

default

Abstract

Background: Propofol is the most commonly used anesthetic sedative for procedural sedation due to its rapid onset and short duration. However, it has been linked to adverse effects on the cardiovascular and respiratory systems, particularly in high-risk patients with obstructive sleep apnea (OSA).20 Remimazolam, a new intravenous anesthetic sedative, has been proven safe and effective during procedural sedation.6 Recent studies show that remimazolam provides effective sedation, hemodynamic stability, and fewer adverse cardiopulmonary effects, which are beneficial for OSA patients.6

Methods: A comprehensive search utilizing CINAHL, Cochrane Library, and MEDLINE analyzed recent articles on the safety and effectiveness of remimazolam and propofol in patients undergoing procedural sedation. The research included studies comparing propofol with remimazolam in individuals with obstructive sleep apnea and the general population.

Results: The study aimed to improve anesthesia professionals' knowledge about remimazolam and propofol in patients with obstructive sleep apnea who undergo procedural sedation. Nine professionals participated in the educational survey, which showed significant improvements in awareness of the undiagnosed population with OSA and mortality rates associated with propofol during procedural sedation. Understanding of remimazolam's pharmacological characteristics and pharmacokinetics also increased. However, there is still a knowledge gap regarding the impact of propofol on upper airway obstruction, hypoxemia episodes, postoperative complications, and the benefits of remimazolam in patients with OSA.

Share

COinS
 

Rights Statement

Rights Statement

In Copyright. URI: http://rightsstatements.org/vocab/InC/1.0/
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).